BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35576287)

  • 21. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study.
    Aydin AM; Singla N; Panwar V; Woldu SL; Freifeld Y; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Westerman ME; Sagalowsky AI; Shariat SF; Lotan Y; Bagrodia A; Kapur P; Margulis V; Krabbe LM
    World J Urol; 2019 Nov; 37(11):2419-2427. PubMed ID: 30759271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BAP1 is overexpressed in black compared with white patients with Mx-M1 clear cell renal cell carcinoma: A report from the cancer genome atlas.
    Paulucci DJ; Sfakianos JP; Yadav SS; Badani KK
    Urol Oncol; 2016 Jun; 34(6):259.e9-259.e14. PubMed ID: 26854086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer.
    Wang XY; Wang Z; Huang JB; Ren XD; Ye D; Zhu WW; Qin LX
    Tumour Biol; 2017 Jun; 39(6):1010428317699111. PubMed ID: 28618948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BAP1 loss defines a new class of renal cell carcinoma.
    Peña-Llopis S; Vega-Rubín-de-Celis S; Liao A; Leng N; Pavía-Jiménez A; Wang S; Yamasaki T; Zhrebker L; Sivanand S; Spence P; Kinch L; Hambuch T; Jain S; Lotan Y; Margulis V; Sagalowsky AI; Summerour PB; Kabbani W; Wong SW; Grishin N; Laurent M; Xie XJ; Haudenschild CD; Ross MT; Bentley DR; Kapur P; Brugarolas J
    Nat Genet; 2012 Jun; 44(7):751-9. PubMed ID: 22683710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.
    Bi M; Zhao S; Said JW; Merino MJ; Adeniran AJ; Xie Z; Nawaf CB; Choi J; Belldegrun AS; Pantuck AJ; Kluger HM; Bilgüvar K; Lifton RP; Shuch B
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2170-5. PubMed ID: 26864202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis.
    Oka S; Inoshita N; Miura Y; Oki R; Miyama Y; Nagamoto S; Ogawa K; Sakaguchi K; Kondoh C; Kurosawa K; Urakami S; Takano T; Okaneya T
    Urol Oncol; 2018 Aug; 36(8):365.e9-365.e14. PubMed ID: 29853346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling Renal Cell Carcinoma in Mice:
    Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
    Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.
    Friedhoff J; Schneider F; Jurcic C; Endris V; Kirchner M; Sun A; Bolnavu I; Pohl L; Teroerde M; Kippenberger M; Schwab C; Kaczorowski A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing A; Duensing S
    Cancer Immunol Immunother; 2023 Jun; 72(6):1603-1618. PubMed ID: 36562826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.
    Wang SS; Gu YF; Wolff N; Stefanius K; Christie A; Dey A; Hammer RE; Xie XJ; Rakheja D; Pedrosa I; Carroll T; McKay RM; Kapur P; Brugarolas J
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16538-43. PubMed ID: 25359211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Machine learning-based unenhanced CT texture analysis for predicting BAP1 mutation status of clear cell renal cell carcinomas.
    Kocak B; Durmaz ES; Kaya OK; Kilickesmez O
    Acta Radiol; 2020 Jun; 61(6):856-864. PubMed ID: 31635476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.
    Zhou Q; Qi Y; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Xu L; Dai B; Guo J; Zhu Y; Zhang W; Xu J
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32371459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.
    Szalai E; Wells JR; Ward L; Grossniklaus HE
    Ophthalmology; 2018 Feb; 125(2):203-209. PubMed ID: 28823399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BAP1 germline mutation in two first grade family members with uveal melanoma.
    Maerker DA; Zeschnigk M; Nelles J; Lohmann DR; Worm K; Bosserhoff AK; Krupar R; Jägle H
    Br J Ophthalmol; 2014 Feb; 98(2):224-7. PubMed ID: 24187051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stabilization of MCRS1 by BAP1 prevents chromosome instability in renal cell carcinoma.
    Peng J; Ma J; Li W; Mo R; Zhang P; Gao K; Jin X; Xiao J; Wang C; Fan J
    Cancer Lett; 2015 Dec; 369(1):167-74. PubMed ID: 26300492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Germline BAP1 mutations predispose also to multiple basal cell carcinomas.
    de la Fouchardière A; Cabaret O; Savin L; Combemale P; Schvartz H; Penet C; Bonadona V; Soufir N; Bressac-de Paillerets B
    Clin Genet; 2015 Sep; 88(3):273-7. PubMed ID: 25080371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.